Observational study of Pertuzumab,Trastuzumab and taxane combination therapy for patient with pretreated HER2-positive advanced or recurrent breast cancer.
- Conditions
- advanced or recurrent breast cancer
- Registration Number
- JPRN-UMIN000013607
- Lead Sponsor
- Shonankamakura General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1) Patient with history of severe allergy. 2) Patient with history of Pertuzumab treatment. 3) Patient with other malignancy under treatment. 4) Patient with active infectious disease. 5) Patient with severe complications, 6) Patient with history of interstitial neumonitis to pulmonary fibrosis. 7) Patient with uncontrollable pleural effusion or ascites. 8) Patient with symptomatic brain metastasis. 9) Pregnant women, nursing mothers, women with possibility of pregnancy or women with no intention to contraception. 10) Patient with psychiatric disease who were considered to be inappropriate. 11)Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to progression
- Secondary Outcome Measures
Name Time Method Response rate Duration of treatment without taxane Safety